Join a study

GHRI recruits Group Health members and others to participate in studies that help us evaluate innovative ways to diagnose, treat, and prevent disease—all key to our mission of improving health and health care for everyone.

Because of how our studies must be designed, they often require highly specific eligibility criteria.

The Institute is currently looking for people to participate in the following research projects:


Research at Group Health is reviewed by oversight committees that include Group Health staff and consumers. These committees ensure that:

Participants’ privacy and rights are protected. Researchers follow strict standards to guard the privacy of medical records and study information.

Participation is strictly voluntary. When people decide not to participate in a study, it doesn’t affect their care at Group Health in any way.

If you qualify for one of the studies that’s currently recruiting participants, please consider taking part. And, if you know others who might be interested, please pass the word.


Expect Study

Do you have low back pain? Just starting one of these treatments?

The EXPECT study needs your help to learn what people expect from treatments like these. We are trying to reach people before or immediately after their first visit!

Begin the survey

How you can help.

Simply answer a few questions to make sure you are eligible, and then complete a research survey online about your back pain and your expectations of the treatment you’re starting. Your experiences and opinions will help researchers conduct new studies to test how well these treatments work for people like you. You will also receive up to $30 to thank you for your contribution to back pain research.

What is the online survey like?

Who can take the online survey?
People who are just starting or planning to start massage, acupuncture, yoga, or chiropractic care as a treatment for low back pain, and who haven’t used this treatment in the past 3 years may be eligible for this study. To be eligible, you must:

Ready to find out if you’re eligible?

If you have questions or want more information about the EXPECT study, please call the project manager, Heidi Berthoud, at 206-442-5240.

This study is led by researchers from the University of Arizona, the University of Washington, and Group Health Research Institute in Seattle. Our funding comes from the National Institutes of Health.


Pneumococcal Conjugate Dose Ranging Vaccine Study

that is a common cause of serious infections, including bloodstream infections and pneumonia. Infants and persons over 65 years of age are at highest risk of these infections. There are currently two pneumococcal vaccines that have been approved by the U.S. Food and Drug Administration (FDA) for use in adults 50 years of age and older: Pneumovax®23 (PPV23) and Prevnar13® (PCV13).

Why is this study being done?The purpose of this study is to see whether giving two injections of PCV13 to adults who have been previously vaccinated with PPV23 improves the pneumococcal immune response. The immune response to two injections of PCV13 in adults previously vaccinated with PPV23 will be compared with 1) response to one injection of PCV13 in adults previously vaccinated with PPV23 and 2) response to one injection of PCV13 in adults who have never received PPV23.

Who can participate? Adults 55 through 64 years of age in general good health who have received one dose of PPV23 between three and seven years ago are currently being enrolled in this study. People who have medical conditions that affect the immune system or are taking medications that affect the immune system may not be in the study. There are also other conditions or circumstances that may make someone ineligible for this study.

What is involved? This study involves 3 visits within a 6 month period. The study visits will be at the Group Health Research Clinic in the Metropolitan Park East building in downtown Seattle. The enrollment visit includes either 1 or 2 injections of PCV13, and all 3 clinic visits include a blood draw.

Participants will be paid $75 for each of the 3 in-person visits completed.

Lisa Jackson, MD, MPH, senior investigator at the Group Health Research Institute, is the principal investigator for the study.

If you might be interested in participating and would like more information about the Pneumococcal Conjugate Dose Ranging Vaccine Study, call us at 206-287-2061 or toll-free at 1-866-883-6772, or e-mail with your contact information.

To view the study forms see the Pneumococcal Conjugate Dose Ranging Vaccine Study on our Study Information and Forms page.



If you are currently enrolled in a GHRI study and are looking for study forms, please see our Study Information and Forms page.

If you would like to know where GHRI’s research clinic is located, please see our Driving Directions to GHRI Clinic page.